3852
C. Sudhakar et al. / Tetrahedron Letters 53 (2012) 3850–3852
Table 3
Antimicrobial activity of compounds 3 and 4
Test pathogen
Minimum inhibitory concentration (MIC lg/ml)
Compound 3
Compound 4
Neomycin (Control)
Staphylococcus aureus MTCC 96
Bacillus subtilis MTCC 121
S. aureus MLS 16 MTCC 2940
Micrococcus luteus MTCC 2470
Klebsiella planticola MTCC 530
Escherichia coli MTCC 739
—
9.37
9.37
—
18.75
—
18.75
18.75
18.75
18.75
18.75
18.75
18.75
4.68
18.75
—
9.37
4.68
—
4.68
18.75
Pseudomonas arruginosa MTCC 2453
(human breast adenocarcinoma) Hela (human cervical cancer), and
Neuro-2a (mouse neuroblastoma). Doxorubicin was used as the
positive control. The MTT assay (according to the method of Mos-
mann5) was utilized to evaluate the activity. IC50 value with each
cell line was determined after four individual observations (Table
2).
The results showed that compound 3 possessed significant
cytotoxicity against the first four cell lines while compound 4
against all of the five cell lines. The latter exhibited higher activity
against MCF-4 and Neuro-2a cell lines.
The antimicrobial activity of compounds 3 and 4 was also tested
against several bacterial organisms: Staphylococcus aureus (MTCC
96), Bacillus subtilis (MTCC 121), S. aureus MLS16 (MTCC 2940),
Micrococcus luteus (MTCC 2470), Klebsiella planticola (MTCC 530),
Escherichia coli (MTCC 739), and Pseudomonas arruginosa (MTCC
2453) Neomycin was used as the positive control and microtiter
broth dilution method was applied to determine the activity.6
The minimum inhibitory concentration (MIC) value with each
pathogen was evaluated after four individual observations (Table
3). The results indicated that the antimicrobial activity of both
the compounds 3 and 4 is promising. They showed highest activity
against E-coli. Compound 3 also showed significant activity against
B. subtilis.
References and notes
1. (a) Patel, A. D.; Freyer, A. J.; Webl, R. L.; Zuber, G.; Reichwein, R.; Bean, M. F.;
Faucettle, L.; Johnson, R. K. Tetrahedron 1977, 53, 1583; (b) McPherson, D. D.;
Cordell, G. A.; Soejarto, D. D.; Pizzuto, J. M.; Fong, H. H. S. Phytochemistry 1983,
27, 2835; (c) McPherson, D. D.; Che, T. T.; Cordell, G. A.; Soejarto, D. D.; Pezzuto,
J. M.; Fong, H. H. S. Phytochemistry 1986, 25, 167; (d) Che, C. T.; McPherson, D. D.;
Cordell, G. A.; Fong, H. H. S. J. Nat. Prod. 1986, 49, 561; (e) Ragasa, C. Y.; Hofilena,
J. G.; Rideout, J. A. J. Nat. Prod. 2002, 65, 1107; (f) Srinivas, K. V. N. S.; Rao, Y. K.;
Mahender, I.; Das, B.; Krishna, K. V. S. R.; Kishore, K. H.; Murthy, U. S. N.
Phytochemistry 2003, 63, 789; (g) Kalauni, S. K.; Awale, S.; Tezuka, Y.; Banskola,
A. H.; Luin, T. Z.; Kadota, S. Chem. Pharm. Bull. 2005, 53, 214.
2. (a) Das, B.; Madhusudhan, P. Tetrahedron Lett. 1998, 39, 9099; (b) Das, B.;
Venkataiah, B.; Kashinatham, A. Tetrahedron 1999, 55, 6585; (c) Ramesh, G.;
Harikishore, K.; Murthy, V. S. N. ARKIVOC 2003, IX, 126; (d) Das, B.; Krishnaiah,
M.; Venkateshwarlu, K.; Das, R. Nat. Prod. Commun. 2006, 1, 225.
3. (a) McPherson, D. D.; Che, C.-T.; Cordell, G. A.; Soejarto, D. D.; Pezzuto, J. M.;
Fong, H. H. S. Phytochemistry 1986, 25, 167; (b) Yodsaoue, O.; Karalai, C.;
Ponglimanont, C.; Tewtrakul, S.; Chantrapromma Tetrahedron 2011, 67, 6838.
4. (a) Westphalen, T. Berichte 1915, 48, 1064; (b) Lettré, H.; Muller, I. Berichte 1937,
1947, 70; (c) Rodig, O. R.; Brown, P.; Zaffaroni, P. J. Org. Chem. 1961, 26, 2431.
5. Mosmann, T. J. Immunol. Methods 1983, 65, 55.
6. (a) Amsterdam, D. In Antibiotics in Laboratory Medicine; Lomen, V., Ed., 4th ed.;
Williams and Wilkins: Baltimore MD, 1996; p 52 e111; (b) Das, B.; Shinde, D. B.;
Kanth, B. S.; Kamle, A.; Kumar, C. G. Eur. J. Med. Chem. 2011, 46, 3124.
7. General experimental procedure: BF3-OEt2 (0.5 mmol) was added dropwise to a
solution of compound (1 or 2) in dry CH2Cl2 (25 mL) under nitrogen atmosphere.
The mixture was stirred at room temperature and the reaction was monitored by
TLC. After completion, the reaction mixture was quenched with distilled water
(5 mL) and the mixture was extracted with CH2Cl2 (3 ꢁ 10 mL). The combined
organic portions were washed with water (2 ꢁ 10 mL), dried over anhydrous
Na2SO4, and concentrated under vacuum. The crude product was subjected to
column chromatography to obtain a pure compound (3 or 4). The following
compounds (amounts and eluting solvents are given) were obtained according to
the increasing order of polarity: compound 3 (20 mg (66%), hexane–EtOAc, 78:22),
compound 4 (23 mg (76%), hexane–EtOAc, 72:28). Compound 3: White solid, mp
In conclusion, we have carried out BF3-mediated interesting
conversions of two natural cassane diterpenoids to generate com-
pounds with impressive cytotoxic and antimicrobial properties.7
Acknowledgements
95–97 °C, yield 66%, ½a D25
ꢂ
+26.8 (c 0.2, CHCl3), IR: 3448, 1721, 1636, 1456,
1238 cmꢃ1 1H and 13C NMR: Table 1; HREIMS: m/z 443.2187 [M+Na]+ (Calcd for
;
The authors thank CSIR and UGC, New Delhi for financial assis-
tance. They are also thankful to NMR, Mass, and IR Divisions of IICT
for spectral recording.
C
27H32O4Na: m/z 443.2198). Compound 4: White solid, mp 169–171 °C, yield 76%,
+18.4(c0.2,CHCl3);IR:3446,1724,1459,1280 cmꢃ1;1Hand13CNMR:Table1;
HREIMS: m/z 469.2369 [M+Na]+ (Calcd for C29H34O4Na :m/z 469.2382).
½ ꢂ
a 2D5